


## (R)-BMS-816336

Cat. No.:	HY-101930B		
CAS No.:	1009583-83-8		
Molecular Formula:	C <sub>21</sub> H <sub>27</sub> NO <sub>3</sub>		
Molecular Weight:	341.44		
Target:	11β-HSD		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 300 mg/mL (878.63 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.9288 mL	14.6439 mL	29.2877 mL
		5 mM		0.5858 mL	2.9288 mL	5.8575 mL
10 mM			0.2929 mL	1.4644 mL	2.9288 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 7.5 mg/mL (21.97 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 7.5 mg/mL (21.97 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 7.5 mg/mL (21.97 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	(R)-BMS-816336 (Compound 6n-1) is a potent and orally active inhibitor of human, mouse and cynomolgus monkey 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC <sub>50</sub> s of 14.5 nM, 50.3 nM and 16 nM, respectively [1].
IC <sub>50</sub> & Target	IC <sub>50</sub> : 14.5 nM (Human 11β-HSD1), 50.3 nM (Mouse 11β-HSD1) and 16 nM (Cynomolgus monkey 11β-HSD1)[1]
In Vivo	During the in vivo studies of BMS-816336 (Compound 6n-2) in animals, its enantiomer (R)-BMS-816336 (Compound 6n-1) in the plasma samples, together with trace amount of Ketone A are detected. The interconversion of BMS-816336 and (R)-BMS-

---

816336 take place via the intermediate Ketone A through physiological oxidation and reduction process. In vivo studies in rat, dog, and cynomolgus monkey, the plasma ratios of (R)-BMS-816336/BMS-816336 decrease in the order: dog > rat > cynomolgus monkey<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Ye XY, et al. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem. 2017 Jun 22;60(12):4932-4948.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA